NCT02523391View on ClinicalTrials.gov

Bioequivalence Study of Capsule and Tablet Formulations of TA-8995

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Dyslipidaemia
Interventions
DRUG

TA-8995

Capsule

DRUG

TA-8995

Tablet

Trial Locations (1)

LS2 9LH

Covance Clinical Research Unit Ltd, Leeds

All Listed Sponsors
lead

Xention Ltd

INDUSTRY

NCT02523391 - Bioequivalence Study of Capsule and Tablet Formulations of TA-8995 | Biotech Hunter | Biotech Hunter